Investors > Investor Information

Webcast ImageWebcast - Replay
Jefferies 2nd Annual Healthcare Conference
06/26/08 at 11:15 a.m. ET
Webcast ImageWebcast - Replay
Vivus Investor Luncheon
06/10/08 at 11:30 a.m. PT
Webcast ImageWebcast - Replay
Vivus at Canaccord Adams Diabetes & Obesity Conference
06/06/08 at 12:20 p.m. PT
VVUS (Common Stock)
ExchangeNASDAQ
Price$7.49
Change (%) Stock is Up 0.17 (2.32%)
Volume493,986
Data as of 07/03/08 1:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health. The investigational pipeline includes: Qnexa™, which is in Phase 3 for the treatment of obesity and Phase 2 for the treatment of diabetes; Testosterone MDTS®, for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); and avanafil, for which a Phase 2 study has been completed for the treatment of erectile dysfunction (ED). MUSE® is approved and currently on the market for the treatment of ED. For more information on clinical trials and products, please visit the company's web site at www.vivus.com.

Recent NewsMore >>
06-26-08VIVUS Announces New Data from Qnexa Diabetes Study
06-20-08VIVUS to Present at the Jefferies 2nd Annual Healthcare Conference
06-13-08VIVUS Announces Presentation of Qnexa Data at the 2008 BIO International Convention
06-10-08Qnexa Reduces Hemoglobin A1c by 1.2 Percent in 28 Weeks
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Vivus posts new information to the site. Just enter your e-mail address and click Submit.
 

VIVUS, Inc. 1172 Castro Street Mountain View, CA 94040

Home | About VIVUS | Products | Research & Development | News RoomConsumers & Patients | Healthcare Professionals | Investors

Copyright © 2004 VIVUS, All rights reserved
VM 372120604